Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FCRL3/CD307c drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCRL3 ECD-Fc Recombinant Protein High purity (>95% by SDS-PAGE), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. Suitable for affinity and binding assays. |
View FCRL3 Products |
| Gene Delivery | FCRL3 Promise-ORF / Lentivirus Full-length human FCRL3 ORF for stable cell line construction. Ideal for cell-based binding assays and flow cytometry validation. |
View FCRL3 Products |
| Benchmark Ab | Anti-FCRL3 Recombinant Antibody Recombinant positive control antibody based on public clinical/patent sequences. Sequence verified, high purity. |
View FCRL3 Products |
| Validator | FCRL3 siRNA Set Target-specific siRNA pool for knockdown verification in primary B cells or Treg functional assays. |
View FCRL3 Products |
| Related Target A | FCRL5 Subfamily homolog. Crucial for off-target selectivity screening and comparative B-cell lineage targeting. |
View FCRL5 Products |
| Related Target B | CTLA4 Synergistic regulatory T cell (Treg) marker. FCRL3 is highly expressed on Treg subsets; co-targeting or comparative assays are vital for immune tolerance studies. |
View CTLA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species reactivity validation (Cyno/Mouse) | Human and Cynomolgus FCRL3 ortholog proteins available with >95% purity and validated sequence identity. |
| Subfamily counter-screening (FCRL1-5 cross-reactivity) | Complete FCRL family recombinant protein panel (FCRL1, FCRL2, FCRL4, FCRL5) strictly verified by mass spectrometry to eliminate off-target binding. |
| Lack of clinical positive controls | Sequence-verified clinical benchmark antibodies (biosimilars) available for assay calibration. |
| Target specificity verification | Sequence-validated siRNA sets included for target-specific knockdown verification in cell-based assays. |
Live FCRL3/CD307c R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FCRL3/CD307c therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-specific immune cell engagers and Treg-targeted immunotherapies. As first-generation autoimmune therapies reach clinical evaluation, the next wave of R&0 is targeting FCRL3 as a key checkpoint in regulatory T cell (Treg) plasticity and B-cell mediated autoimmune diseases like Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Blocking/Depleting) | Academic Institutes, Biopharma Startups | Rheumatoid Arthritis, SLE, Autoimmune Thyroiditis | High-affinity binding assays (Need HEK293-expressed FCRL3 ECD-Fc) |
| Bispecific Antibodies (Treg/B-cell engagers) | Global Immunotherapy Developers | Solid Tumors, Autoimmune Diseases | Dual-targeting validation (Need FCRL3 and CD3/CTLA4 panel proteins) |
| Cell Therapy (Treg Modulation) | Treg-focused Biotech Companies | Transplant Rejection, Severe Autoimmunity | Stable cell line construction (Need FCRL3 Lentivirus for surface expression) |